Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Exelixis, Inc.

< Previous 1 2 3 4 5 Next >
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Advances Board Refreshment Plan
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Reiterates Commitment to Shareholder Value Creation
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces $550 Million Share Repurchase Program
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Update on Patent Litigation with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 —  Presentation to be webcast on www.exelixis.com  —
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
From Exelixis, Inc.
Via Business Wire
Tickers CTLT EXEL
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.